We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 319

Post-Actavis rulings focus on what constitutes a payment in reverse-payment settlements

  • Skadden Arps Slate Meagher & Flom LLP
  • -
  • USA
  • -
  • January 21 2015

Nearly a year and a half after the Supreme Court's landmark decision in Federal Trade Commission v. Actavis, Inc., 133 S.Ct. 2223 (2013), the hotly

IPtronix sues Avago for antitrust violations for filing allegedly baseless Section 337 complaint

  • King & Spalding LLP
  • -
  • USA
  • -
  • January 16 2015

On December 29, 2014, IPtronics Inc. and Mellanox Technologies Denmark, APS filed a complaint in the U.S. District Court for the Northern District of

In re: Nexium plaintiffs seek new trial

  • Patterson Belknap Webb & Tyler LLP
  • -
  • USA
  • -
  • January 7 2015

As reported previously, the first post-Actavis jury verdict in a "reverse payment" antitrust case handed a win to the defendants. Now, plaintiffs in

Life sciences: patent extension strategies and antitrust global update

  • DLA Piper LLP
  • -
  • USA
  • -
  • January 5 2015

In DLA Piper's 'Life Sciences: Patent extension strategies and antitrust' global update video, we cover global antitrust and competition issues

Lessons learned from first Final Written Decision in a Hatch-Waxman related inter partes review

  • Paul Hastings LLP
  • -
  • USA
  • -
  • December 16 2014

Last week, the Patent Trial and Appeal Board issued Final Written Decisions in three inter partes review proceedings upholding the patentability of

FTC commissioner brill urges Congress to act on patent trolls

  • McDermott Will & Emery
  • -
  • USA
  • -
  • December 15 2014

In a speech at the American Antitrust Association (AAI) and Computer & Communications Industry Association (CCIA) Conference on Innovation, Patents

Made in Canada approach to pay for delay: bureau at odds with US approach

  • Cassels Brock & Blackwell LLP
  • -
  • USA
  • -
  • December 8 2014

Last week, a US Federal Court ruled that AstraZeneca Plc's payment to Ranbaxy Laboratories Ltd. to delay a generic version of heartburn medication

FDA citizen petition may give rise to antitrust liability; factual issues exist concerning whether ANDA infringement claim was objectively baseless

  • Fish & Richardson PC
  • -
  • USA
  • -
  • December 6 2014

Federal Circuit reverses summary judgment of no sham litigation related to an infringement suit and FDA citizen’s petition but affirms summary

FTC settles with patent assertion entity to prevent future deceptive conduct that would trigger penalties of up to $16,000 per letter

  • Akin Gump Strauss Hauer & Feld LLP
  • -
  • USA
  • -
  • December 4 2014

Patent assertion entities (PAEs), sometimes referred to as nonpracticing entities or, derisively, as "patent trolls," generate revenue by acquiring

Antitrust-related recent developments: DOJ settles gun-jumping case, FTC issues fines for failure to submit HSR filing and FTC settles with patent assertion entity

  • Akin Gump Strauss Hauer & Feld LLP
  • -
  • USA
  • -
  • December 4 2014

On Friday, November 7, 2014, two companies agreed to pay $4.95 million to settle U.S. Department of Justice (DOJ) allegations that the companies